BioStock Life ScienceSummit 2018

Connecting Innovation& Capital.

FO

TO

: C

OB

E /

SC

IEN

CE

VIL

LA

GE

SC

AN

DIN

AV

IA

biotech | pharma | diagnostics | devices

We proudly welcome you to the first

ever BioStock Life Science Summit.

Hosted at Medicon Village in Lund where

innovation and capital connect, we aim to

make BLSS the Nordic region’s premier

meeting place for entrepreneurs and

investors, always offering an exciting

sneak peek into the future of biotech,

pharma, diagnostics and health devices.

We hope you will enjoy this day.

Sincerely, the Biostock Team

Moderator

Jonas Söderström, CEO BioStock

Agenda BioStock Life Science Summit 2018

13:00 Opening remarks BioStock, Jonas Söderström CEO

13:05 Xintela, Evy Lundgren-Åkerlund CEO

13:25 Idogen, Lars Hedbys CEO

13:45 Q&A Panel w. Kerstin Jacobsson, Medicon Village Evy Lundgren-Åkerlund, Xintela and Lars Hedbys, Idogen

13:55 Aptahem, Mikael Lindstam CEO

14:15 Break - refreshments

14:25 2cureX, Ole Thastrup CEO

14:45 Liv Diagnostics, Johan Bjurquist CEO

15:05 Øresund Investor Climate Report, Johan Ny

15:15 Q&A Panel w. Johan Ny NY Consulting, Johan Bjurquist Liv Diagnostics, Ole Thastrup 2CureX and Fredrik Rahl Sedermera Fondkommission

15:25 Break - Coffee & Snacks

15:45 Respiratorius, Johan Drott CEO

16:05 Cereno Scientific, Sten R. Sörensen CEO

16:25 Gabather, Michael Robin-Witt CEO

16:45 BrainCool, Martin Waleij CEO

17:05 Pila Pharma, Dorte X. Gram CEO

17:15 Break - Refreshments

17:30 Nuevolution, Alex Haahr Gouliaev CEO

17:50 Cantargia, Göran Forsberg CEO

18:10 RhoVac, Anders Ljungqvist CEO

18:30 Alligator Bioscience, Per Norlén CEO

18:50 Immunicum, Carlos de Souza CEO

19:10 Q&A panel w. Carl Borrebaeck Lunds Universitet, Per Norlén Alligator Bioscience, Carlos de Souza and Alex Karlsson-Parra Immunicum

19:30 Networking drinks & buffet

About BioStock

BioStock is the Nordic region’s leading digital news and analytics service focusing exclusively on the life science sector. By webcasting the BioStock Life Science Summit 2018 live via our multi-channel media platform and extensive media partner network, the presentations, panel discussions and industry insights will be reaching a broad base of professional and retail investors in Sweden as well as internationally. BioStock’s daily news briefings are closely monitored by a majority of life science investors and industry executives in the Nordic region. To subscribe and learn more about BioStock, feel free to explore our free content at biostock.se.

DisclaimerThe information in this folder has been collected from a variety of public sources which BioStock considers to be reliable, and reasonable efforts have been made to verify the information whenever feasible, but BioStock cannot and does not warrant that the information is accurate or complete. The information herein may be partly based on forward-looking statements which involve several risks and uncertainties, many of which are external and thus beyond the individual company ’s control. The folder shall be considered as containing general information, and is not intended as investment advice, individual or otherwise. All investments in financial instruments are connected to risks. BioStock does not provide investment advice. Biostock shall not take responsibility for any direct or indirect damages that may be caused due to any decisions made in connection with the information in this folder. This folder is not directed to legal or natural persons in jurisdictions where the provision of the folder would be in breach of mandatory applicable law. By choosing to read this folder, you understand and accept this disclaimer.

25k 55k 250k 82%Newsletter Monthly Web Total Investor SWE C-levelSubscribers Visitors (av.) Network Reach Subscribers

Xintela

Xintela is a Swedish biomedical company working in the fields of regenerative medicine and cancer, with particular focus on cartilage damage and brain tumours. The key to Xintela’s operations is the company ’s patented marker technology XINMARK®. Xintela’s markers are specific proteins which work as ”recognition flags” on the surface of certain cells. The markers make it possible to identify and select certain types of stem cells which can develop into cartilage cells. Thus, Xintela can provide a unique way of ensuring the quality of stem cells to be used in repairing damaged cartilage. Xintela has established state of the art GMP-production facilities at Medicon Village. The company recently announced that Bauerfeind AG is to become a major stakeholder in Xintela following a directed new share issue of 50MSEK.

Xintela is presented by Evy Lundgren-Åkerlund, CEO

Homepage xintela.seTicker & Market XINT Nasdaq First North Shares issued 30M (updated 19 Oct 2018)Market Cap 188 MSEK (updated 19 Oct 2018)CEO Evy Lundgren-ÅkerlundChairman Gregory Batcheller

Major stakeholders Capital % Votes %Evy Lundgren-Åkerlund 13,61 13,61ALMI Invest 6,96 6.96Avanza Pension 6,57 6,57Fredrik Olsson 5,37 5,37Pär Åke Oldentoft 5,34 5,34Updated 30 September 2018

Idogen

Located at Medicon Village in Lund, Idogen is developing tolerogenic cell therapies to prevent the patient ’s immune system from attacking biological agents, transplanted organs or the body ’s own cells or tissues. The company ’s focus is on the treatment of autoimmune diseases, organ transplant rejection and patients who have developed anti-drug antibodies. Idogen’s most advanced product candidate, IDO 8, is designed for patients with severe haemophilia A who have developed anti-drug antibodies against their critical treatment with coagulation factor VIII. IDO 8 is currently in preclinical phase and a clinical phase I/II study is planned to be initiated early 2020. The pipeline also includes IDO T, a tolerogenic cell therapy to prevent organ transplant rejection, primarily in kidney transplants. This project is also in preclinical development, with clinical development planned for the end of 2020. Idogen also collaborates with a research group from Oxford University to develop a treatment method for rheumatoid arthritis.

Idogen is presented by Lars Hedbys, CEO

Homepage idogen.comTicker & Market IDOGEN Spotlight Stock Market Shares issued 21M (updated 18 Oct 2018) Market Cap 43MSEK (updated 18 Oct 2018) CEO Lars HedbysChairman Agneta Edberg

Major stakeholders Capital % Votes %HCN Group AB 10,94 10,94Avanza Pension 5,15 5,15Ventac Holding 3,87 3,87Nils Berntsson 3,37 3,37Olov Sjögren 3,27 3,27Updated 30 June 2018

Cereno Scientific

Located at the AstraZeneca Bioventure Hub in Gothenburg, Cereno Scientific’s focus is on diseases that affect the circulatory system and the blood vessels. The company is developing the drug candidate CS1 to prevent blood clots with an innovative new approach, where instead of inhibiting the blood's ability to coagulate like conventional blood-thinning medications, the drug candidate utilizes and strengthens the body's own pro-solving defense system. The goal is to achieve better efficiency while reducing the risk of uncontrolled bleeding, the most serious side effect of existing treatments on the market. The company has completed clinical phase I studies with CS1 with positive results and has entered into an agreement with the OCT Group on the implementation of a clinical phase II. Cereno Scientific expects to start a clinical phase II study in early 2019. Cereno has a strategic partnership with Galenica since 2016, when the companies joined forces to develop Cereno Scientific’s main drug candidate.

Cereno Scientific is presented by Sten R. Sörensen, CEO

Homepage cerenoscientific.seTicker & Market CRNO B Spotlight Stock Market Shares issued 12M (updated 18 Oct 2018) Market Cap 39MSEK (updated 18 Oct 2018) CEO Sten SörensenChairman Anders Svensson

Major stakeholders Capital % Votes %Sverker Jern 10,59 18,63Niklas Bergh 10,47 18,42GU Ventures 9,14 5,74Pia Larsson 5,53 3,47Galenica AB 5,10 3,20Updated 30 June 2018

Liv Diagnostics

Liv Diagnostics is Swedish diagnostics company, located at the AstraZeneca Bioventure Hub in Gothenburg. The company is developing a product aimed at measuring the migration behavior of tumor cells, thus providing an indication of the risk for the cancer spreading. The lead product is CellRACE, which is focused on the development of a prototype for diagnosing migratory breast cancer cells. Liv Diagnostics also sees potential for the product in other cancer forms. The project was developed based on severeal years of research from Karolinska Institutet. The company's business model aims to develop the CellRACE product to a stage where a partnership with a global player in the industry can be established.

Liv Diagnostics is presented by Johan Bjurquist, CEO

Homepage livdiagnostics.sePrivately owned CEO Johan BjurquistChairman Patrik Sundh

Major stakeholders

Liv Diagnostics was founded in 2016 by a research team together with a group of investors and entrepreneurs. Liv Diagnostics has received financing from SWElife / VINNOVA and a growth loan from the Västra Götalands-regionen. As of today, the company is privately owned.

BrainCool

BrainCool is a Swedish medical device company located at Medicon Village, Lund. The company develops patented medical cooling technologies focusing on two business areas: Brain Cooling and Pain Management. The medical cooling technology, also called therapeutic hypothermia, lowers patients’ body temperature to help reduce the risk of injury to the brain following a period of insufficient blood flow due to an ischemic event. The company develops cooling systems for treatment of stroke-, cardiac arrest- and migraine patients, as well as products for the prevention of oral mucositis and neuropathy, major severe side effects of cancer treatment. The estimated annual market value of each of the treatment areas is significant: stroke ($ 3 billion), cardiac arrest (current sales of three major players $ 150 million with annual growth of 30% - 40%) and oral mucositis ($ 1 billion). BrainCool recently spun off PolarCool, a company focused on treating sports related concussions and mild traumatic brain injury.

BrainCool is presented by Martin Waleij, CEO

Homepage braincool.seTicker & Market BRAIN Spotlight Stock Market Shares issued 36M (updated 18 Oct 2018) Market Cap 395MSEK (updated 18 Oct 2018) CEO Martin WaleijChairman Jens Kinnander

Major stakeholders Capital % Votes %Nordnet Pension 13,07 13,07Avanza Pension 12,84 12,84Cormac Invest AB 2,28 2,28Swedbank Försäkring 1,80 1,80Christer Atterklev 0,79 0,79Updated 30 June 2018

Respiratorius

Respiratorius is a biotech company located at Medicon Village in Lund. Respiratorius develops new and effective candidate drugs for treatment of cancer, COPD and asthma. The project portfolio also includes the development of a biomarker for cardiovascular PET-imaging. The oncology drug project (VAL-001) is currently in clinical phase I for first-line treatment of Diffuse Large B-Cell Lymphoma (DLBCL). In the COPD and asthma projects, the company has developed two new classes of proprietary drug substances (RESP-1000 and RESP-2000 series), which compared to current practice have superior bronchodilating effect on small airways. These substances, which utilize new methods of action, are developed in ex-vivo experiments on human lung tissue with the RESP-HSAT technology platform. The company is actively seeking partnership with Big Pharma for the continued development of its candidate drugs. An ideal partner for Respiratorius would have the capacity to finance and lead the clinical development and at the same time assume responsibility for production, marketing and sales.

Respiratorius is presented by Johan Drott , CEO

Homepage respiratorius.comTicker & Market RESP Spotlight Stock Market Shares issued 157M (updated 19 Oct 2018) Market Cap 242MSEK (updated 19 Oct 2018) CEO Johan DrottChairman Christer Fåhræus

Major stakeholders Capital % Votes %Christer Fåhraeus 15,63 15,63Avanza Pension 7,53 7,53Valcuria Holding AB 7,17 7,17Hans Harvig 2,48 2,48Hartmut Wiese 1,34 1,34Updated 30 June 2018

Nuevolution

Nuevolution is a Scandinavian biopharmaceutical company located in Copenhagen. The company develops drug treatments for human diseases within oncology and chronic inflammatory diseases. Nuevolution is focused on the development of tablet based medicines for treatment of severe chronic inflamatory diseases, programs enabling future medicines in immuno-oncology and personalized medicines for the treatment of cancer. The company's patent protected drug discovery platform Chemetics enables DNA encoded synthesis of billions of chemically diverse drug-like small molecule compounds, and the efficient screening and optimization of these, facilitating effective identification of drug candidates. The company is partnering with companies like Novartis, Janssen Biotech, Boehringer Ingelheim, GlaxoSmithKline, Merck & Co, Lexicon Pharmaceuticals, as well as leading oncology research institutions.

Nuevolution is presented by Alex Gouliaev, CEO

Homepage nuevolution.comTicker & Market NUE Nasdaq Stockholm Shares issued 49M (updated 19 Oct 2018) Market Cap 732MSEK (updated 19 Oct 2018) CEO Alex GouliaevChairman Stig Pedersen

Major stakeholders Capital % Votes %Sunstone LSV Fund I K/S 20,70 20,70SEB Venture Capital 20,40 20,40Stiftelsen Industrifonden 18,20 18,20SEB Utvecklingsstiftelse 6,60 6,60SEB-Stiftelsen 5,00 5,00Updated 29 March 2018

2cureX

2cureX was founded in 2006 with the vision of improving treatment efficiency of cancer patients. The company has developed IndiTreat™, a test which helps oncologists determine the optimal treatment for the individual cancer patients through a fast, effective and comprehensive approach. IndiTreat™ has been tested in more than 900 patients with promising results and in October 2017 a clinical trial started using IndiTreat™ with stage IV colorectal cancer patients and the product is currently being clinically validated in colorectal and ovarian cancer. 2CureX was recently granted CE-IVD, which means that IndiTreat™ can be sold in Europe. The company have successfully led multiple collaborations with both commercial and academic partners and 2cureX expects IndiTreat® to become a standard tool in the treatment design for cancer patients.

2CureX is presented by Ole Thastrup, CEO

Homepage 2curex.comTicker & Market 2CUREX Nasdaq Stockholm First North Shares issued 10,3M (updated 19 Oct 2018) Market Cap 147 MSEK (updated 19 Oct 2018) CEO Ole ThastrupChairman Povl-Andre Bendz

Major stakeholders Capital % Votes %OT 311 ApS 36,3 36,3ClearStream Banking 16,3 16,3FORCE Technology 9,9 9,9Sydbank A/S 6,2 6,2Grith Hagel 5,8 5,8Updated 29 June 2018

Alligator Bioscience

Alligator is a research-based biotechnology company developing antibody-based pharmaceuticals for cancer treatment. The company specializes in the development of tumour-directed immunotherapies, in particular agonistic mono- and bispecific antibodies. In immunotherapy, the patients’ immune system is activated to treat the cancer. The term tumour-directed means that the drug is administered or designed such that the pharmacological effect is localized to the tumour. This results in an advantageous efficacy and safety profile. Alligator Bioscience is primarily active in the early phases of drug development, from the idea stage to clinical phase II trials. This includes identification of innovative modes of action for pharmaceuticals, producing and optimizing new drug candidates, evaluation of preclinical efficacy and safety, and finally confirmatory clinical studies in cancer patients. In August 2015, the company outlicensed global development and commercialization rights of ADC-1013/JNJ-64457107 to Janssen Biotech Inc.

Alligator Bioscience is presented by Per Norlén, CEO

Homepage alligatorbioscience.seTicker & Market ATORX Nasdaq Stockholm Shares issued 71,3M (updated 19 Oct 2018) Market Cap 1916MSEK (updated 19 Oct 2018) CEO Per NorlénChairman Peter Benson

Major stakeholders Capital % Votes %Banque Internationale à Luxembourg SA 19.1 19.1Johnson & Johnson Innovation 8.1 8.1Sunstone Life Science Ventures Fund II K/S 8.1 8.1Lars Spånberg 4.5 4.5Goldman Sachs & Co LLC 3.6 3.6Updated 31 August 2018

Aptahem

Aptahem is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved. The company ’s primary drug candidate, Apta-1, is being developed with the aim of preventing the high mortality rate caused by organ and tissue damage in sepsis patients, among others. The company holds patent protection in strategic target markets and actively seeks business development opportunities with potential collaborators. During 2018 Aptahem has reported positive results from toxicology- and safety studies in the Apta-1 pre-clinical program. The company is currently preparing the next steps in Apta-1 pre-clinical program.

Aptahem is presented by Mikael Lindstam, CEO

Homepage aptahem.comTicker & Market APTA Spotlight Stock MarketShares issued 15,8M (updated 19 Oct 2018) Market Cap 20MSEK (updated 19 Oct 2018) CEO Mikael LindstamChairman Kjell G. Stenberg

Major stakeholders Capital % Votes %Ivar Nordqvist 17,19 17,19Avanza Pension 7,31 7,31Gunvald Berger 2,82 2,82Nils Qvarner 2,42 2,42AB Svedala Finans 1,92 1,92Updated 30 June 2018

Cantargia

Cantargia specialises in antibody-based cancer treatment. The company ’s lead drug candidate CAN04, is a patented antibody therapy which has a dual mechanism of action. It fights cancer by activating the immune system and blocking signals that lead to tumour growth. CAN04 is initially focused on non-small cell lung cancer (NSCLC) and pancreatic cancer and clinical trials started in 2017. Treatment with CAN04 has the potential to become an important part of modern immuno-oncology. During 2018 Cantargia completed a list change to Nasdaq Stockholm. Recently Cantargia presented positive phase I clinical data from the CANFOUR study with CAN04 at the ESMO Congress 2018 in Germany, showing a good safety profile and encouraging initial effects.

Cantargia is presented by Göran Forsberg, CEO

Homepage cantargia.comTicker & Market CANTA Nasdaq Stockholm Shares issued 66,1M (updated 19 Oct 2018) Market Cap 1323MSEK (updated 19 Oct 2018) CEO Göran ForsbergChairman Magnus Persson

Major stakeholders Capital % Votes %Sunstone Life Science Ventures 9,02 9,02Första AP-fonden 6,87 6,87Avanza Pension 5,25 5,25Fjärde AP-fonden 4,63 4,63Andra AP-fonden 3,32 3,32Updated 30 September 2018

Gabather

Gabather has four main focus areas: anti-psychotics, anti-depressants and anxiolytics, analgesics, as well as cognition-enhancing treatments, including for Alzheimer ’s disease. Many patents for blockbuster drugs in these areas are expiring, and generic copies are causing a decline in profits for major pharmaceutical companies. Therefore, there is currently a high demand for new developments within the above target areas. Gabather has decided to primarily focus on the area of anti-psychotics, with continued development of the lead substance GT-002. The total market for anti-psychotics was estimated at 11.7 billion US dollars in 2015. Gabather has completed in vitro and in vivo experiments on the substances GT-001 through GT-006. The substances were tested in models for psychosis and anxiety, with promising results.

Gabather is presented by Michael Robin-Witt , CEO

Homepage gabather.comTicker & Market GABA Stockholm Nasdaq First North Shares issued 5,1M (updated 19 Oct 2018) Market Cap 60MSEK (updated 19 Oct 2018) CEO Michael-Robin Witt (acting CEO)Chairman Svein Mathisen

Major stakeholders Capital % Votes %Avanza Pension 9,44 9,44ALMI 4,4 4,4Mogens Nielsen 3,04 3,04Olov Sterner 2,89 2,89Jakob Nilsson 2,45 2,45Updated 30 September 2018

Pila Pharma

PILA PHARMA is a privately held clinical stage pharmaceutical company based in Malmö, Sweden.The company is developing a novel type of oral anti-diabetic agent: a TRPV1 antagonist for the treatment of diabetes. Pila Pharma owns issued use-patents giving the right to treat diabetes and obesity with TRPV1 antagonists. The company ’s lead clinical development drug candidate, XEN-D0501, entered the first clinical trials in type-2 diabetic patients in 2017.

Pila Pharma is presented by Dorte X. Gram, CEO

Homepage pilapharma.comPrivately owned CEO Dorte X. GramChairman Erik Nerpin

Major stakeholders

Pila Pharma is founded by and partially owned by XENIA PHARMA, Denmark. Further, ALMI Invest, Sweden has invested in the compa-ny three times. ALMI Företagspartner, Sweden has awarded an inn-ovation loan and in June 2016 and March 2017, a number of private investors have joined the group of Pila Pharma investors.

Immunicum

Immunicum is a biotech company located in Gothenburg and Stockholm that develops cancer therapies that activate the patient ’s own immune system to destroy cancer cells, i.e. cancer immunotherapy or immuno-oncology (I/O). The aim of these treatments is to trigger the immune system to detect and attack cancer cells and enable other anti-cancer treatments to work more effectively. The company's most advanced project ilixadencel, currently in clinical phase II, is focused on the treatment of kidney cancer. The project portfolio includes seven other projects against various tumor diseases, including liver cancer. Immunicum is open for collaboration with partners from the pharma/biotech industry and academic research groups in the I/O field. Especially in the development of therapeutics with complementary mechanisms of action, such as checkpoint inhibitors, immunomodulators and kinase inhibitors. Recently Immunicum presented preclinical results showing anti-tumor synergy between its lead product ilixadencel and a checkpoint inhibitor or an immune enhancer at the ESMO Congress.

Immunicum is presented by Carlos de Sousa, CEO

Homepage immunicum.seTicker & Market IMMU Nasdaq Stockholm Shares issued 50M (updated 19 Oct 2018) Market Cap 459MSEK (updated 19 Oct 2018) CEO Carlos de SousaChairman Michael Oredsson

Major stakeholders Capital % Votes %Avanza Pension 7,70 7,70Martin Lindström 5,90 5,90Holger Blomstrand Byggnads 5,80 5,80Nordnet Pension 5,10 5,10Aagcs Nv Re Aacb Nv Re Tm 3,30 3,30Updated 31 March 2018

RhoVac

RhoVac is a biotechnology company conducting research and development in immunotherapy, focusing on therapeutic cancer vaccines. The company ’s primary focus is to develop a drug with the potential to prevent or limit metastases in metastatic cancers. The RhoVac cancer vaccine product RV001 is designed to stimulate the immune system to target metastatic cancer cells, regardless of which type of cancer the patient may have. Thus, the potential market for RhoVac’s immunotherapy is significant, should the company complete the planned clinical studies successfully. RhoVac intends to license or sell all, or part of, operations as soon as possible after clinical phase I/II studies have been completed. During 2018 Rhovac has presented positive top-line results on safety and on immune activation in the phase I/II clinical trial RhoVac-001 in prostate cancer patients.

RhoVac is presented by Anders Ljungqvist, CEO

Homepage rhovac.comTicker & Market RHOVAC Spotlight Stock MarketShares issued 9,5M (updated 19 Oct 2018) Market Cap 376MSEK (updated 19 Oct 2018) CEO Anders LjunqvistChairman Mikael Ørum

Major stakeholders Capital % Votes %RQ Solution 14,07 14,07Ventac Holding 12,49 12,49Avanza Pension 7,45 7,45Nordnet Pension 4,35 4,35Nils Berntsson 2,10 2,10Updated 30 September 2018

S u b s c r i b e t o o u r n e w s l e t t e r t o l e a r n a b o u t f u t u r e e v e n t s

B I O S T O C K . S E

W E T H A N K O U R PA R T N E R S :

N Y H E T S B Y R Å N D I R E K T | M E D I C O N V I L L A G E | E N D P O I N T S N E W S

N Y C O N S U LT I N G